

Christopher Bowen Managing Director and Chief Regulatory Counsel Legal Department

December 6, 2013

## VIA E-MAIL

Ms. Melissa Jurgens Office of the Secretariat Commodity Futures Trading Commission Three Lafayette Centre 1155 21st Street, N.W. Washington, D.C. 20581



RE: SUPPLEMENTAL SUBMISSION: CME Submission No. 13-459S: Additional Supplemental Information Relating to the CME Standard-Sized and E-Micro INR/USD Market Maker Incentive Program. Subject to Freedom of Information Act Protection.

Dear Ms. Jurgens:

Previously, pursuant to Submission No. 13-459 dated December 6, 2013, Chicago Mercantile Exchange Inc. ("CME" or "Exchange") notified the Commodity Futures Trading Commission ("CFTC" or "Commission") of plans to modify the CME Standard-Sized and E-Micro INR/USD Market Maker Incentive Program ("Program").

In this letter, CME is providing the Commission with certain additional information related to the obligations and incentives under the Program. The additional supplemental information is provided in Appendix A, for which a request for confidential treatment and detailed written justification is being simultaneously submitted to the Commission. A copy of the request for confidential treatment and detailed written justification is included with this supplemental filing.

Modifications appear below with additions underscored and deletions overstruck.

CME certifies that the Program and proposed modifications comply with the Commodity Exchange Act ("CEA") and the regulations thereunder. A concise explanation and analysis of the operation, purpose and effect of the Program was provided in Submission No. 13-459. There were no substantive opposing views to this Program.

CME certifies that a description of this submission has been concurrently posted on CME's website at <u>http://www.cmegroup.com/market-regulation/rule-filings.html</u>.

If you require any additional information regarding this submission, please contact Tim Elliott at 312-466-7478 or via e-mail at <u>tim.elliott@cmegroup.com</u>, or contact me at 212-299-2200. Please reference our CME Submission No. 13-459S in any related correspondence.

Sincerely,

/s/ Christopher K. Bowen Managing Director and Chief Regulatory Counsel

## Attachment: Appendix A

1 North End Avenue New York, NY 10282 T 212 299 2200 F 212 299 2299 christopher.bowen@cmegroup.com cmegroup.com



Christopher Bowen Managing Director and Chief Regulatory Counsel Legal Department

December 6, 2013

VIA E-MAIL

Ms. Melissa Jurgens Office of the Secretariat Commodity Futures Trading Commission Three Lafayette Centre 1155 21st Street, N.W. Washington, D.C. 20581

CONFIDENTIAL TREA REQUESTED

## Re: FOIA Confidential Treatment Request

Dear Ms. Jurgens:

By e-mail dated today, December 6, 2013, Chicago Mercantile Exchange Inc. ("CME" or "Exchange") submitted a supplemental rule certification filing (Submission No. 13-459S) to the Commodity Futures Trading Commission ("CFTC" or "Commission"). This supplemental filing includes an appendix ("Appendix A"), which is attached.

Pursuant to Sections 8 and 8(a) of the Commodity Exchange Act ("CEA"), as amended, and Commission Regulation 145.9(d), CME requests confidential treatment of Appendix A, on the grounds that Appendix A contains confidential commercial information of the submitter (CME). Pursuant to Commission Regulation 145.9(d)(5), CME requests that confidential treatment be maintained for Appendix A <u>until further notice from CME</u>. We also request that the Commission notify the undersigned immediately after receiving any FOIA request for said Appendix A or any other court order, subpoena or summons for same. Finally, we request that we be notified in the event the Commission intends to disclose such Appendix A to Congress or to any other governmental agency or unit pursuant to Section 8 of the CEA. CME does not waive its notification rights under Section 8(f) of the CEA with respect to any subpoena or summons for such Appendix A.

Please contact the undersigned at (212) 299-2200 should you have any questions concerning this letter.

Sincerely,

/s/ Christopher K. Bowen Managing Director and Chief Regulatory Counsel

Enclosure: Exhibit 1